Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
needs, particularly among patients who do not achieve adequate control with PPIs. Nevertheless, advancements in diagnostic approaches and the introduction of next-generation therapies, such as BLI5100 (Braintree Laboratories), linaprazan glurate (Cinclus Pharma), and others, are expected to sustain market growth from 2025 to 2034. LAS VEGAS Jan. 22, 2026 /PRNewswire/ -- DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Gastroesophageal Reflux Disease Market Summary The market size for gastroesophageal reflux disease was found to be USD 3.3 billion in the United States in 2024. VOQUEZNA established its early presence as t
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 [Yahoo! Finance]Yahoo! Finance
- Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026GlobeNewswire
- Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Should Phathom's US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? [Yahoo! Finance]Yahoo! Finance
- Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]Seeking Alpha
PHAT
Earnings
- 10/30/25 - Beat
PHAT
Sec Filings
- 1/27/26 - Form 4
- 1/27/26 - Form SCHEDULE
- 1/23/26 - Form 4
- PHAT's page on the SEC website